Evidence map›Paper›PMID 39059270›Full record

ArticleMolecular genetics and metabolism

Initial results from the PHEFREE longitudinal natural history study: Cross-sectional observations in a cohort of individuals with phenylalanine hydroxylase (PAH) deficiency.

Shawn E Christ, Georgianne Arnold, Uta Lichter-Konecki, Gerard T Berry, Dorothy K Grange, Cary O Harding, Elaina Jurecki, Harvey Levy, Nicola Longo, Hadley Morotti and 3 more

Abstract read
In one paragraph

Article in Molecular genetics and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Phenylketonuria in adults: we know plenty, but there is much more to learn.The American journal of clinical nutrition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shawn E ChristUniversity of Missouri, Columbia, MO, United States of America.
Georgianne ArnoldUniversity of Pittsburgh, Pittsburgh, PA, United States of America.
Uta Lichter-KoneckiUniversity of Pittsburgh, Pittsburgh, PA, United States of America.
Gerard T BerryBoston Children's Hospital, Harvard Medical School, Boston, MA, United States of America.
Dorothy K GrangeWashington University School of Medicine, St. Louis, MO, United States of America.
Cary O HardingOregon Health & Science University, Portland, OR, United States of America. Electronic address: hardingc@ohsu.edu.
Elaina JureckiNational PKU Alliance, San Ramon, CA, United States of America.
Harvey LevyBoston Children's Hospital, Harvard Medical School, Boston, MA, United States of America.
Nicola LongoUniversity of Utah, Salt Lake City, UT, United States of America.
Hadley MorottiOregon Health & Science University, Portland, OR, United States of America.
Stephanie SacharowBoston Children's Hospital, Harvard Medical School, Boston, MA, United States of America.
Janet ThomasChildren's Hospital of Colorado, University of Colorado School of Medicine, Aurora, CO, United States of America.
Desiree A WhiteWashington University in St. Louis, St. Louis, MO, United States of America.

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive HyperphenylalaninemiaU54HD100982 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI HARDING, CARY O. · 2019 to 2023
$7.9M
NCATS NIH HHS UL1 TR002369NICHD NIH HHS U54 HD100982
6 · The paper itself

Abstract

Over fifty years have passed since the last large scale longitudinal study of individuals with PAH deficiency in the U.S. Since then, there have been significant changes in terms of treatment recommendations as well as treatment options. The Phenylalanine Families and Researchers Exploring Evidence (PHEFREE) Consortium was recently established to collect a more up-to-date and extensive longitudinal natural history in individuals with phenylketonuria across the lifespan. In the present paper, we describe the structure and methods of the PHEFREE longitudinal study protocol and report cross-sectional data from an initial sample of 73 individuals (5 months to 54 years of age) with PAH deficiency who have enrolled. Looking forward, the study holds the promise for advancing the field on several fronts including the validation of novel neurocognitive tools for assessment in individuals with PKU as well as evaluation of the long-term effects of changes in metabolic control (e.g., effects of Phe-lowering therapies) on outcome.

Indexed as

PhenylalaninePhenylalanine HydroxylasePhenylketonuriasAdolescentAdultChildChild, PreschoolCross-Sectional StudiesFemaleHumansInfantLongitudinal StudiesMaleMiddle AgedYoung AdultPhenylalaninePhenylalanine HydroxylaseExecutive functionMotor abilityNeuropsychologyNIH toolboxPhenylketonuriaProcessing speed

Identifiers

PMID39059270
PMCPMC12349655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.